MX2007005137A - Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. - Google Patents
Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.Info
- Publication number
- MX2007005137A MX2007005137A MX2007005137A MX2007005137A MX2007005137A MX 2007005137 A MX2007005137 A MX 2007005137A MX 2007005137 A MX2007005137 A MX 2007005137A MX 2007005137 A MX2007005137 A MX 2007005137A MX 2007005137 A MX2007005137 A MX 2007005137A
- Authority
- MX
- Mexico
- Prior art keywords
- aryl
- specifically
- alkyl
- aralkyl
- cycloalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 heteroaryt Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 abstract 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63048104P | 2004-11-23 | 2004-11-23 | |
| PCT/IB2005/003461 WO2006056845A1 (en) | 2004-11-23 | 2005-11-14 | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007005137A true MX2007005137A (es) | 2007-06-22 |
Family
ID=35708411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007005137A MX2007005137A (es) | 2004-11-23 | 2005-11-14 | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7446121B2 (https=) |
| EP (1) | EP1819681B1 (https=) |
| JP (1) | JP2008520642A (https=) |
| KR (1) | KR20070084455A (https=) |
| AP (1) | AP2007003979A0 (https=) |
| AR (1) | AR052244A1 (https=) |
| AT (1) | ATE439347T1 (https=) |
| AU (1) | AU2005308575A1 (https=) |
| BR (1) | BRPI0518300A2 (https=) |
| CA (1) | CA2590533C (https=) |
| CR (1) | CR9102A (https=) |
| DE (1) | DE602005016009D1 (https=) |
| EA (1) | EA200700875A1 (https=) |
| ES (1) | ES2328384T3 (https=) |
| GT (1) | GT200500338A (https=) |
| IL (1) | IL182569A0 (https=) |
| MA (1) | MA30108B1 (https=) |
| MX (1) | MX2007005137A (https=) |
| NL (1) | NL1030487C2 (https=) |
| PA (1) | PA8653401A1 (https=) |
| PE (1) | PE20061057A1 (https=) |
| TN (1) | TNSN07202A1 (https=) |
| TW (1) | TW200626556A (https=) |
| UY (1) | UY29220A1 (https=) |
| WO (1) | WO2006056845A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006056845A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| WO2006087630A2 (en) * | 2005-02-16 | 2006-08-24 | Warner-Lambert Company Llc | OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| US7834050B2 (en) | 2006-03-29 | 2010-11-16 | Duke University | Small molecule insulin mimetics absent quinones |
| WO2008059372A2 (en) * | 2006-11-17 | 2008-05-22 | Pfizer Products Inc. | Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt |
| KR20130132816A (ko) * | 2010-10-21 | 2013-12-05 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 1-(헤테로시클릭 카르보닐) 피페리딘 |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| CA3085086C (en) | 2011-12-06 | 2023-08-08 | Delta Faucet Company | Ozone distribution in a faucet |
| CN108463437B (zh) | 2015-12-21 | 2022-07-08 | 德尔塔阀门公司 | 包括消毒装置的流体输送系统 |
| MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| CN114425329B (zh) * | 2022-03-10 | 2024-04-19 | 西安凯立新材料股份有限公司 | 孕烯醇酮醋酸酯合成用催化剂及其制备方法和应用 |
| US12274680B2 (en) | 2022-09-13 | 2025-04-15 | II George William Creasy | Treatment of benign prostatic hypertrophy with capsinoids |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1154810B (de) | 1961-04-01 | 1963-09-26 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
| US3262977A (en) | 1962-03-10 | 1966-07-26 | Chinoin Gyogyszer Es Vegyeszet | N-aralkyl-1, 1-diphenyl-propylamine derivatives |
| BE637389A (https=) | 1962-09-13 | |||
| US3857952A (en) | 1967-12-22 | 1974-12-31 | May & Baker Ltd | Certain benzene derivatives useful in treating cardiac disorders |
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
| US3683080A (en) | 1970-08-28 | 1972-08-08 | Procter & Gamble | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue |
| BE795735A (fr) | 1972-03-06 | 1973-06-18 | Cerm Cent Europ Rech Mauvernay | Nouvelles ethylenediamines substituees a activite cardiovasculaire |
| GB1435139A (en) | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
| US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| JPS608117B2 (ja) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | 新生理活性物質エステラスチンおよびその製造法 |
| DE2719912C3 (de) | 1977-05-04 | 1979-12-06 | Bayer Ag, 5090 Leverkusen | Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen |
| DE2733747C2 (de) | 1977-07-27 | 1979-09-27 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol |
| EP0002097B1 (en) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| CA1147342A (en) | 1977-10-12 | 1983-05-31 | Kazuo Imai | Process of producing novel phenylethanolamine derivatives |
| JPS5953920B2 (ja) | 1977-12-28 | 1984-12-27 | 東洋醸造株式会社 | 新規なアミノ糖化合物およびその製法 |
| CA1121290A (en) | 1978-02-14 | 1982-04-06 | Yasuji Suhara | Amino sugar derivatives |
| JPS559058A (en) | 1978-07-06 | 1980-01-22 | Dainippon Pharmaceut Co Ltd | 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| ES505959A0 (es) | 1980-10-09 | 1982-09-01 | Hoechst Ag | Procedimiento para la preparacion de un inactivador de alfa-amilasa |
| DE3166093D1 (en) | 1981-01-05 | 1984-10-18 | Takeda Chemical Industries Ltd | N-substituted pseudo-aminosugars, their production and use |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
| US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US4567175A (en) | 1983-06-03 | 1986-01-28 | Tanabe Seiyaku Co., Ltd. | 8-Chloro-1,5-benzothiazepine derivatives |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| DK520784A (da) | 1984-01-21 | 1985-07-22 | Hoechst Ag | Cycliske polypeptider, deres fremstilling og anvendelse |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| FI860755A0 (fi) | 1984-06-22 | 1986-02-20 | Sandoz Ag | Pyrazolanaloger av mevolonolakton och deras derivat, foerfaranden foer deras framstaellning samt deras andvaendning. |
| US4631286A (en) | 1984-10-25 | 1986-12-23 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
| US4634765A (en) | 1984-12-18 | 1987-01-06 | Merrell Dow Pharmaceuticals Inc. | Homodisaccharide hypoglycemic agents |
| GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| US5061798A (en) | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4957971A (en) | 1986-07-07 | 1990-09-18 | Warner-Lambert Company | Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| US4808621A (en) | 1986-07-07 | 1989-02-28 | Warner-Lambert Company | Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| GB2196003A (en) | 1986-09-11 | 1988-04-20 | Nat Res Dev | Iodo-and bromo-tamoxifen derivatives |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5192772A (en) | 1987-12-09 | 1993-03-09 | Nippon Shinyaku Co. Ltd. | Therapeutic agents |
| NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| EP0344383A1 (en) | 1988-06-02 | 1989-12-06 | Merrell Dow Pharmaceuticals Inc. | Novel alpha-Glucosidase inhibitors |
| DE3836675A1 (de) | 1988-10-28 | 1990-05-03 | Hoechst Ag | Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung |
| DE3918364A1 (de) | 1989-06-06 | 1990-12-13 | Hoechst Ag | 3-desmethyl-2-methyl-mevalonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
| US5185351A (en) | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
| IT1237793B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5504078A (en) | 1990-06-08 | 1996-04-02 | Merrell Dow Pharmaceuticals Inc. | α-glucosidase inhibitors |
| JPH054943A (ja) | 1990-08-30 | 1993-01-14 | Sagami Chem Res Center | 光学活性β，δ−ジケト酸エステル及びその還元体 |
| US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| CA2098167C (en) | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| EP0647234A1 (en) | 1992-06-26 | 1995-04-12 | Pfizer Inc. | Steroidal glycosides for treating hypercholesterolemia |
| US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| EP0580550B1 (en) | 1992-07-21 | 1997-10-22 | Novartis AG | Oxamic acid derivatives as hypocholesteremic agents |
| US5728704A (en) | 1992-09-28 | 1998-03-17 | Pfizer Inc. | Substituted pyridmidines for control of diabetic complications |
| DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
| CA2128044C (en) | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US7501441B1 (en) | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
| EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| JPH08143457A (ja) | 1994-11-21 | 1996-06-04 | Microbial Chem Res Found | 酵素阻害剤および高脂血症抑制剤 |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| GB9504066D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Phosphate derivatives of ureas and thioureas |
| FI974437A7 (fi) | 1995-06-06 | 1997-12-05 | Pfizer | Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina |
| CA2224062C (en) | 1995-06-06 | 2001-09-04 | Pfizer Limited | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO1996040640A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| KR100389518B1 (ko) | 1995-07-17 | 2003-11-15 | 워너-램버트 캄파니 엘엘씨 | 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴) |
| JPH09173638A (ja) * | 1995-12-25 | 1997-07-08 | Hudson Soft Co Ltd | 相対時間による派生シナリオ起動方法 |
| AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
| TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
| TW506836B (en) | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| JPH10310578A (ja) * | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | ３−フェニルピラゾール化合物 |
| NZ335162A (en) | 1996-11-27 | 2000-01-28 | Pfizer | Apo b-secretion/mtp inhibitory amides |
| PE107899A1 (es) | 1997-09-09 | 1999-11-17 | Glaxo Group Ltd | Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria |
| US6245911B1 (en) | 1997-12-05 | 2001-06-12 | Eisai Co., Ltd. | Donepezil polycrystals and process for producing the same |
| ES2284219T3 (es) | 1997-12-19 | 2007-11-01 | Pfizer Ireland Pharmaceuticals | Procedimiento de sintesis de 1,3-dioles. |
| PA8471201A1 (es) | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| DK1086706T3 (da) | 1999-03-31 | 2004-03-08 | Eisai Co Ltd | Stabiliserede sammensætninger indeholdende nootropiske lægemidler |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| US6521607B1 (en) | 1999-09-23 | 2003-02-18 | Pharmacia Corporation | (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| US6586433B2 (en) | 1999-09-23 | 2003-07-01 | Pharmacia Corporation | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| US20030171377A1 (en) | 2001-08-29 | 2003-09-11 | Bigge Christopher Franklin | Antidiabetic agents |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| EA008928B1 (ru) | 2002-11-26 | 2007-08-31 | Пфайзер Продактс Инк. | Активаторы рецепторов, активируемых пролифератором пероксисом (ppar ) |
| KR20050088190A (ko) | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
| US7250444B2 (en) * | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
| AU2005237428A1 (en) | 2004-04-16 | 2005-11-10 | Warner-Lambert Company Llc | Novel imidazoles |
| WO2006056845A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
-
2005
- 2005-11-14 WO PCT/IB2005/003461 patent/WO2006056845A1/en not_active Ceased
- 2005-11-14 AP AP2007003979A patent/AP2007003979A0/xx unknown
- 2005-11-14 MX MX2007005137A patent/MX2007005137A/es not_active Application Discontinuation
- 2005-11-14 KR KR1020077011587A patent/KR20070084455A/ko not_active Ceased
- 2005-11-14 AU AU2005308575A patent/AU2005308575A1/en not_active Abandoned
- 2005-11-14 JP JP2007542152A patent/JP2008520642A/ja active Pending
- 2005-11-14 EP EP05801166A patent/EP1819681B1/en not_active Expired - Lifetime
- 2005-11-14 AT AT05801166T patent/ATE439347T1/de not_active IP Right Cessation
- 2005-11-14 BR BRPI0518300-6A patent/BRPI0518300A2/pt not_active Application Discontinuation
- 2005-11-14 CA CA2590533A patent/CA2590533C/en not_active Expired - Fee Related
- 2005-11-14 DE DE602005016009T patent/DE602005016009D1/de not_active Expired - Lifetime
- 2005-11-14 ES ES05801166T patent/ES2328384T3/es not_active Expired - Lifetime
- 2005-11-14 EA EA200700875A patent/EA200700875A1/ru unknown
- 2005-11-18 US US11/283,264 patent/US7446121B2/en not_active Expired - Fee Related
- 2005-11-21 UY UY29220A patent/UY29220A1/es not_active Application Discontinuation
- 2005-11-21 AR ARP050104871A patent/AR052244A1/es unknown
- 2005-11-21 PE PE2005001361A patent/PE20061057A1/es not_active Application Discontinuation
- 2005-11-22 GT GT200500338A patent/GT200500338A/es unknown
- 2005-11-22 NL NL1030487A patent/NL1030487C2/nl not_active IP Right Cessation
- 2005-11-22 TW TW094140920A patent/TW200626556A/zh unknown
- 2005-11-23 PA PA20058653401A patent/PA8653401A1/es unknown
-
2007
- 2007-04-16 IL IL182569A patent/IL182569A0/en unknown
- 2007-05-03 CR CR9102A patent/CR9102A/es not_active Application Discontinuation
- 2007-05-22 TN TNP2007000202A patent/TNSN07202A1/fr unknown
- 2007-05-23 MA MA29934A patent/MA30108B1/fr unknown
-
2008
- 2008-10-08 US US12/247,434 patent/US20090170852A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2328384T3 (es) | 2009-11-12 |
| IL182569A0 (en) | 2007-07-24 |
| KR20070084455A (ko) | 2007-08-24 |
| AP2007003979A0 (en) | 2007-06-30 |
| WO2006056845A1 (en) | 2006-06-01 |
| ATE439347T1 (de) | 2009-08-15 |
| AR052244A1 (es) | 2007-03-07 |
| US7446121B2 (en) | 2008-11-04 |
| TNSN07202A1 (fr) | 2008-11-21 |
| CA2590533A1 (en) | 2006-06-01 |
| EP1819681B1 (en) | 2009-08-12 |
| DE602005016009D1 (de) | 2009-09-24 |
| US20090170852A1 (en) | 2009-07-02 |
| NL1030487C2 (nl) | 2007-01-08 |
| CA2590533C (en) | 2010-09-07 |
| US20060111422A1 (en) | 2006-05-25 |
| PE20061057A1 (es) | 2006-11-09 |
| UY29220A1 (es) | 2006-06-30 |
| JP2008520642A (ja) | 2008-06-19 |
| BRPI0518300A2 (pt) | 2008-11-11 |
| EP1819681A1 (en) | 2007-08-22 |
| PA8653401A1 (es) | 2006-09-08 |
| NL1030487A1 (nl) | 2006-05-24 |
| TW200626556A (en) | 2006-08-01 |
| MA30108B1 (fr) | 2009-01-02 |
| GT200500338A (es) | 2006-06-22 |
| AU2005308575A1 (en) | 2006-06-01 |
| EA200700875A1 (ru) | 2007-12-28 |
| CR9102A (es) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200100359A (et) | Kristalliline bis[(E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül](3R,5S)-3,5-dihüdroksühept-6-enool happe]kaltsiumisool | |
| MX2007005137A (es) | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. | |
| UY28577A1 (es) | Proceso químico e intermedios | |
| AU2001280438A1 (en) | Substituted heterocyclic amides | |
| MY145460A (en) | Biaryl ether urea compounds | |
| DE69931393D1 (de) | Antithrombotische amide | |
| TR200200270T2 (tr) | Bir HMG redüktaz inhibitörü içeren farmasötik bileşimler. | |
| DE69907963D1 (de) | Heteroaromatische amide als inhibitoren von faktor xa | |
| ATE272633T1 (de) | Aromatische amiden | |
| DK1373230T3 (da) | Enantiselektiv syntese af azetidinon mellemprodukter | |
| DE69915687D1 (de) | Heterocyclische amide als inhibitoren von faktor xa | |
| ATE440833T1 (de) | Antithrombotische diamide | |
| HRP20030435B1 (en) | Process for the preparation of donepezil | |
| WO2003004457A3 (en) | Preparation process for atorvastatin and intermediates | |
| BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
| DE602006019710D1 (de) | Magnesiumsalze von hmg-coa-reduktase-hemmern | |
| TH85268A (th) | ตัวยับยั้ง HMG Co-A รีดักเตสที่มีพื้นฐานเป็นไพราโซลใหม่ | |
| DE60213541D1 (de) | Discodermolid-Analoga und ihre pharmazeutische Verwendung | |
| UA98767C2 (uk) | Фармацевтичні проміжні сполуки в синтезі інгібіторів ацетилхолінестерази (асе) | |
| EA200200187A1 (ru) | Производное 1,4,5,6-тетрагидропиримидина в качестве ингибитора витронектина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |